| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $34.0M | — | -18.1% |
| SG&A Expense | $18.9M | — | +92.1% |
| Operating Income | -$52.8M | — | -3.0% |
| Net Income | -$50.5M | — | -7.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $248.5M | +4.3% | — |
| Current Assets | $289.4M | -8.5% | — |
| Total Assets | $290.6M | -12.1% | — |
| Current Liabilities | $33.1M | +6.7% | — |
| Stockholders' Equity | $257.5M | -10.4% | -28.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$32.6M | — | +27.7% |
| Capital Expenditures | $17K | — | -51.4% |
| Investing Cash Flow | $35.0M | — | +135.6% |
| Financing Cash Flow | $7.9M | — | +37.4% |
| Free Cash Flow | -$32.6M | — | +27.7% |